Bharat Biotech's iNNOVACC: India's 1st intranasal vaccine to cost Rs 800 in private markets, Rs 325 for govt

Bharat Biotech's iNNOVACC: India's 1st intranasal vaccine to cost Rs 800 in private markets, Rs 325 for govt iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion-stabilized SARS-CoV-2 spike protein. This vaccine candidate was evaluated in phases I, II and III clinical trials with successful results. https://ift.tt/lIYBNH0

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Women in India Report Higher Sleep Deprivation Than Men

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018